A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function

Pfizer

Status and phase: Completed; Phase 1

Conditions: Hepatic Insufficiency

Treatments: Drug: CP-690,550

Study type: Interventional

Funder types: Industry

Identifiers

NCT00969813

A3921015

Details and patient eligibility

About

This study is designed to evaluate how CP-690,550 is handled by the body in healthy volunteers who have mild and moderate hepatic impairment compared to healthy volunteers with normal hepatic function. This study will also evaluate the safety and tolerability of CP-690,550.

Enrollment: 18 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy volunteers who have normal liver function, and subjects who have either mild or moderate liver impairment.

Exclusion criteria

• Subjects with severe liver impairment
• Subjects who have weakened immune systems

Trial design

18 participants in 3 patient groups

Normal hepatic function

Experimental group

Treatment:

Drug: CP-690,550

Drug: CP-690,550

Drug: CP-690,550

Mild hepatic impairment

Experimental group

Treatment:

Drug: CP-690,550

Drug: CP-690,550

Drug: CP-690,550

Moderate hepatic impairment

Experimental group

Treatment:

Drug: CP-690,550

Drug: CP-690,550

Drug: CP-690,550